De novo nucleotide biosynthesis and its dynamic regulation are crucial for systemic infection by extraintestinal Escherichia coli

Chu Zhang; Yi Yang; Shuang Wang; Yuying Liu; Xianglin Zhao; Fan Yin; Yawen Hu; Ying Xue; Zixuan Bu; Shaowen Li; Chen Tan; Rui Zhou; Qi Huang

doi:10.1371/journal.ppat.1013889

Abstract

Extraintestinal Escherichia coli (ExPEC) proliferates rapidly in the bloodstream, causing life-threatening systemic infections with high mortality rates. Understanding how ExPEC adapts to the blood environment is essential for elucidating its pathogenesis and identifying potential antimicrobial targets. Using transposon mutagenesis-based high-throughput screening, we systematically identified genes critical for ExPEC growth in serum. Our findings demonstrate that de novo nucleotide biosynthesis genes are indispensable for serum proliferation, and animal infection assays further confirm their vital role in ExPEC virulence. Genetic disruption of this pathway did not affect bacterial stress response or adhesion capacity but severely impaired ExPEC’s intracellular survival in macrophages. Transcriptomic profiling combined with a luminescent reporter system revealed significant upregulation of de novo nucleotide biosynthesis genes during both serum incubation and systemic infection. This upregulation was mediated by the transcriptional repressor PurR, and could be inhibited by purine supplementation. Furthermore, enhanced in vivo fitness was observed for the purR deletion strain, whereas the opposite was seen for the purR overexpression strain, indicating a crucial role for PurR in ExPEC pathogenesis. Quantitative analyses showed that serum incubation significantly depletes intracellular purine pools in ExPEC. Electrophoretic mobility shift assays (EMSA) demonstrated that specific purines modulate PurR-DNA binding affinity. These results suggest that PurR acts as a sensor of intracellular purine concentration changes, regulating de novo nucleotide biosynthesis genes to facilitate host environment adaptation. This study reveals the essential role of de novo nucleotide biosynthesis in ExPEC virulence and describes a pathogenesis mechanism involving nucleotide metabolism regulation to overcome nutritional immunity, offering a foundation for developing therapies against systemic ExPEC infections.

Author summary

Extraintestinal pathogenic Escherichia coli (ExPEC) exhibits a remarkable ability to proliferate in the bloodstream, enabling rapid dissemination throughout the host. Identifying genetic determinants that support ExPEC growth in blood is crucial for understanding its pathogenic mechanisms and discovering potential therapeutic targets. In this study, we identified the critical role of de novo nucleotide biosynthesis genes in serum growth and systemic infection by ExPEC. Moreover, we demonstrated that the de novo nucleotide biosynthesis pathway is significantly upregulated during incubation in serum or during systemic infection. PurR was identified as a key repressor of this pathway and contributed to ExPEC pathogenesis. We further provide biochemical evidence showing that purine levels modulate the DNA-binding affinity of PurR. This mechanism allows PurR to function as a molecular sensor of nucleotide availability, tuning de novo nucleotide biosynthesis gene expression to overcome nutritional constraints within the host. These findings provide valuable insights into ExPEC pathogenesis and highlight promising therapeutic targets.

Citation: Zhang C, Yang Y, Wang S, Liu Y, Zhao X, Yin F, et al. (2026) De novo nucleotide biosynthesis and its dynamic regulation are crucial for systemic infection by extraintestinal Escherichia coli. PLoS Pathog 22(1): e1013889. https://doi.org/10.1371/journal.ppat.1013889

Editor: Franz Narberhaus, Ruhr-Universität Bochum: Ruhr-Universitat Bochum, GERMANY

Received: August 7, 2025; Accepted: January 10, 2026; Published: January 26, 2026

Copyright: © 2026 Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: The raw RNA-sequencing data have been deposited in the NCBI Sequence Read Archive (SRA) database under BioProject accession number PRJNA1302191. All other data are available within the manuscript and/or supporting information files.

Funding: This work was funded by the National Key Research and Development Program of China (2024YFE0104800 to Q.H. and 2021YFD1800401 to R.Z.) and the Hubei Provincial Natural Science Foundation (2024AFB734 to Q.H). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Introduction

Extraintestinal pathogenic Escherichia coli (ExPEC) poses a significant global health threat as a versatile bacterial pathogen capable of causing severe or even life-threatening diseases in both humans and animals [1,2]. The clinical spectrum of ExPEC infections is broad, with primary manifestations including urinary tract infections (UTIs), meningitis with particular concerns in neonates, and sepsis, which has a high mortality risk [3–5]. Of particular concern is that the level of antimicrobial resistance is very high, and vaccine development is a big challenge due to high genomic diversity [2,6–8]. The World Health Organization (WHO) has recognized ExPEC as one of the global priority endemic pathogens requiring urgent control measures [9].

One of the most significant characteristics of ExPEC is its remarkable capacity for rapid proliferation within host environments. Unlike intestinal pathogenic E. coli strains that primarily rely on enterotoxins, for example, Shiga toxins [10], heat-stable and/or heat-labile toxins [11], etc., as major virulence determinants, ExPEC exhibits distinct pathogenic mechanisms, with host survival and immune evasion playing central roles, although toxins have also been reported to be involved in the pathogenesis of ExPEC [12,13]. A well-studied example is the iron acquisition system, in which a large-scale genomic association study revealed a major role of the iron capture systems in the virulence of ExPEC [14]. Also, the iron regulator Fur serves as the key regulator of the ExPEC, controlling expression of a substantial amount of genes in response to the host environment, for example, in the serum [15]. The ability to utilize a variety of amino acids and small peptides has also been revealed to be associated with the pathogenicity of uropathogenic Escherichia coli (UPEC) to cause UTIs [16].

Nucleotide biosynthesis is essential for all organisms, which produces building blocks required for many key cellular processes, including DNA replication, energy metabolism, cell signaling, etc. [17]. There are two pathways that bacteria use to synthesize nucleotides: the de novo biosynthesis pathway and the salvage pathway. The de novo pathway synthesizes nucleotides from precursor molecules, including ribose-5-phosphate and some amino acids [18]. The salvage pathway catalyzes pre-existing purine or pyrimidine bases and nucleosides to synthesize nucleotides [18]. Nucleotide biosynthesis has been reported to play important roles in the pathogenesis of several bacterial pathogens. For example, disrupting the de novo purine biosynthesis constrains intracellular replication of UPEC [19]. In Staphylococcus aureus, the de novo purine biosynthesis but not the salvage pathway is reported to be essential for the virulence [20].

PurR is a key transcriptional repressor of nucleotide biosynthesis in both Gram-negative and Gram-positive bacteria [21,22]. Biochemical studies revealed that most purine biosynthesis and some of the pyrimidine biosynthesis genes are directly regulated by PurR [21]. Recent studies have provided evidence linking PurR to the virulence of pathogenic bacteria. For example, purR mutation results in hypervirulence in S. aureus, which is attributed to its regulatory role in de novo purine biosynthesis [22]. This indicates the important role of transcriptional regulation of nucleotide biosynthesis for bacterial pathogenesis.

ExPEC can lead to serious systemic infections. Although research has identified nucleotide biosynthesis as a contributing factor in the pathogenesis of certain ExPEC strains, such as UPEC [19,23,24], the specific mechanisms by which this contributes to ExPEC virulence, as well as the dynamic regulation of this metabolic pathway during systemic infections, are not well understood.

In this study, transposon mutagenesis screening identified the de novo nucleotide biosynthesis as essential for serum growth of ExPEC. The specific contribution of this pathway to the pathogenesis was investigated. Moreover, our data demonstrated significant upregulation of the pathway during infection and revealed that PurR functions as a metabolic sensor, modulating bacterial adaptation to host environments through purine concentration-dependent regulation of nucleotide biosynthesis.

Results

Genome-wide screening reveals the essential role of de novo nucleotide biosynthesis genes in ExEPC serum survival

In comparison to the commensal intestinal E. coli MC4100 strain, the ExPEC PCN033 (WT) strain demonstrated robust growth in mouse serum (S1 Fig), consistent with its strong ability to proliferate within the host. A genome-wide screening was conducted using transposon (Tn) mutagenesis to identify genes required for serum growth of ExPEC. A total of 4500 Tn mutants were generated using our previously established Tn mutagenesis system [25] and tested for their growth in mouse serum. Compared to the WT strain, eighteen mutants were identified that displayed significantly inhibited growth in the serum (Table 1). Growth curves were further measured with these Tn mutants, revealing that in contrast to the WT strain, these mutants exhibited retarded growth in serum, although they showed a similar growth pattern in LB medium (Fig 1). Notably, genes involved in de novo nucleotide biosynthesis, including purH, purD, pyrC, and carB, were significantly enriched among those identified in the Tn screening. Additionally, several other genes were identified, primarily related to cell envelope biogenesis (rffG, wecA, rfbA, gne), amino acid transport and metabolism (aroA, dadA, sdaA, pepQ), energy production and conversion (narI), lipid transport and metabolism (glxR), and transcription regulation (rfaH and yieP).

Download:

Table 1. Essential genes for ExPEC growth in serum.

https://doi.org/10.1371/journal.ppat.1013889.t001

Download:

Fig 1. Growth curves of Tn mutants.

Overnight cultures of each indicated strain were inoculated 1:100 into LB medium (left panel) or fresh mouse serum (right panel). OD_{600 nm} was measured every 0.5 hours. The ExPEC PCN033 strain served as a positive control with robust growth in serum, while the E. coli MC4100 strain was used as a negative control that was unable to grow in serum.

https://doi.org/10.1371/journal.ppat.1013889.g001

The de novo nucleotide biosynthesis pathway is critical for the virulence of ExPEC

Following the identification of multiple de novo nucleotide biosynthesis genes via Tn screening, we evaluated the contribution of this metabolic pathway to ExPEC virulence using a murine infection model. purH, which was identified in the Tn screening, and two other de novo purine biosynthesis genes, purE and guaB, were selected, and their deletion mutants and complemented strains were constructed. Growth assays showed that ΔpurH, ΔpurE, and ΔguaB were unable to grow in the serum, and complementation of each gene restored the growth, confirming the critical role of the de novo nucleotide biosynthesis pathway for growth in the serum (S2 Fig). The mouse infection model was used to compare the virulence of the mutants with that of the WT strain. It was shown that ΔpurH, ΔpurE, and ΔguaB strains were rapidly cleared in the indicated organ tissues while the WT strain still showed high load at 12, 24, and 36 hours post-infection (hpi), suggesting that disrupting the de novo purine biosynthesis pathway significantly attenuated the virulence of ExEPC (Fig 2A). It was further investigated whether deleting the de novo nucleotide biosynthesis impaired the ability of stress response of ExPEC by testing their growth in the presence of 0.003% H₂O₂ (oxidative stress), 3% SDS (envelop stress), or 5% NaCl (hyperosmotic stress). The results showed that ΔpurH, ΔpurE, and ΔguaB exhibited comparable growth with the WT strain (Fig 2B), suggesting that the attenuated virulence was not attributed to the stress response ability. Cell adhesion experiments were performed, which showed that the deletion of purH, purE, or guaB did not affect the cell adhesion (Fig 2C). In contrast, ΔpurH, ΔpurE, and ΔguaB exhibited defective intracellular survival within macrophages (Fig 2D). These data suggest that disruption of the de novo nucleotide biosynthesis pathway significantly attenuated the virulence of ExPEC, which was attributed to the impaired growth in the serum and within macrophages.

Download:

Fig 2. De novo nucleotide biosynthesis genes are critical for ExPEC virulence.

A. Animal infection assays. Mice were intraperitoneally injected with 2 × 10⁵ CFU of mid-log phase cultures of each indicated strain. Bacterial burdens in tissues were quantified at each indicated time point. B. In vitro stress response assays. Mid-log phase cultures of each strain were diluted to 1 × 10⁶ CFU/ml, and 5 μL of each cell suspension was spotted onto the indicated agar plates, followed by incubation at 37°C. C. Cell adhesion assay. PK-15 cells were infected with mid-log phase cultures of ExPEC PCN033 and its mutants at a multiplicity of infection (MOI) of 10:1 and incubated at 37°C for one hour. The cell culture was then washed twice with sterile PBS, followed by the addition of sterile water and incubation at 4°C for one hour to lyse cells. The lysate was serially diluted and plated on LB agar for bacterial enumeration. D. Intracellular survival assay. Bacterial cultures were mixed with RAW264.7 cells at an MOI of 10:1 and incubated at 37°C for one hour. After washing twice with sterile PBS, unphagocytized bacteria were killed by incubation with PBS containing 50 μg/ml chloramphenicol. Cells were then cultured in fresh DMEM. After two hours, macrophages were lysed as described above for bacterial enumeration. Statistical significance was assessed using one-way ANOVA. Significance levels were defined as ns (not significant), P < 0.05 (*), P < 0.01 (**), P < 0.001 (***), and P < 0.0001 (****).

https://doi.org/10.1371/journal.ppat.1013889.g002

The expression of de novo nucleotide biosynthesis genes is significantly upregulated when incubated in serum and during ExPEC infection

Transcriptomics analysis was conducted to identify differentially expressed genes (DEGs) in ExPEC when cultured in serum compared with LB medium. RNA-sequencing (RNA-seq) revealed that compared with incubation in LB medium, one-hour incubation in fresh serum induced upregulation of 800 genes and downregulation of 709 genes of ExPEC PCN033 (Fig 3A). KEGG enrichment analysis of DEGs demonstrated that the top 10 enriched pathways for upregulated genes included: Two-component system, Terpenoid backbone biosynthesis, Quorum sensing, Pyrimidine metabolism, Purine metabolism, One carbon pool by folate, Nicotinate and nicotinamide metabolism, Mismatch repair, Methane metabolism, and Metabolic pathways. The top ten enriched pathways for downregulated genes comprised: Valine, leucine, and isoleucine degradation, Two-component system, Tryptophan metabolism, Sulfur metabolism, Ribosome, Pyruvate metabolism, Pantothenate and CoA biosynthesis, Oxidative phosphorylation, Nitrogen metabolism, and Microbial metabolism in diverse environments (Fig 3B). Notably, genes involved in both purine and pyrimidine nucleotide biosynthesis showed significant enrichment. Pathway mapping revealed substantial involvement of these genes in de novo nucleotide biosynthesis (Fig 3C). To verify whether de novo nucleotide biosynthesis genes were similarly upregulated during systemic infection, luminescent reporter strains were generated by fusing the promoter regions of purE with the luxCDABE coding sequence. Using constitutive promoter J23110 as a control, significant upregulation of purE gene was observed at 12 hpi and 36 hpi (Fig 3D). These findings collectively demonstrate significant activation of the de novo nucleotide biosynthesis pathway during ExPEC infection.

Download:

Fig 3. De novo nucleotide biosynthesis genes show significant upregulation during serum incubation and infection.

A. Statistics of up- and down-regulated genes in ExPEC after serum incubation. B. KEGG pathway enrichment analysis of differentially expressed genes (DEGs). The DEGs identified in transcriptomic analysis were subjected to KEGG pathway enrichment, with the top 10 enriched pathways shown. C. Schematic diagram of upregulated genes in the de novo nucleotide biosynthesis pathway. Upregulated genes are marked with brown boxes. D. Expression of the purE gene during mouse infection. ExPEC PCN033 carrying either pCDF-J23110-Lux or pCDF-purR-Lux was used to infect mice. Mice were humanely euthanized at indicated time points, followed by tissue collection and homogenization for luminescence measurement and bacterial load quantification. Statistical significance was assessed using one-way ANOVA. Significance levels were defined as ns (not significant) and P < 0.0001 (****).

https://doi.org/10.1371/journal.ppat.1013889.g003

Supplementation of purines in serum inhibited the upregulation of de novo purine biosynthesis genes in ExPEC

It was tested whether the upregulation of de novo purine biosynthesis genes was caused by the scarcity of free purines in serum. The expression of these genes was determined in M9 medium (purine-free) and serum, respectively, with or without supplementation of additional purines. As shown in Fig 4 (purple columns), when ExPEC PCN033 cells were incubated in M9 medium or in serum, significant upregulation of the de novo purine biosynthesis genes purE, purH, and purK was observed. In contrast, when additional guanine or hypoxanthine was supplemented to the M9 medium or serum, the upregulation of these genes was significantly inhibited. These results indicated that the de novo purine biosynthesis genes were upregulated in response to limited environmental availability of free purines.

Download:

Fig 4. Expression analysis of de novo purine biosynthesis genes in ExPEC under different conditions and strains.

Gene expression was determined using RT-qPCR with WT, ΔpurR, and purR-OE strains in M9 medium (A) or serum (B), with or without supplementation of 0.1 mM guanine (Gua) or hypoxanthine (Hyp). Statistical significance was assessed using one-way ANOVA. Significance levels were defined as ns (not significant), P < 0.05 (*), P < 0.01 (**), and P < 0.001 (***).

https://doi.org/10.1371/journal.ppat.1013889.g004

PurR is a transcriptional repressor that regulates the expression of de novo purine biosynthesis genes and plays a role in the pathogenesis of ExPEC

PurR has been previously identified as a transcriptional regulator of nucleotide biosynthesis. To investigate its regulatory role in ExPEC, we constructed a purR deletion strain (ΔpurR) and an overexpression strain (purR-OE). Western blot analysis confirmed the overexpression of PurR in the latter strain (S3 Fig). Since the addition of exogenous purines inhibited the upregulation of de novo purine biosynthesis genes when ExPEC cells were incubated in M9 medium or serum (Fig 4), it was next tested whether this regulation was mediated by PurR by testing the expression of the purine biosynthesis genes in ΔpurR and purR-OE strains, with or without supplementation of additional purines. The results showed that in both M9 medium and serum, deletion of purR significantly upregulated the expression of purine biosynthesis genes (Figs 4A & 4B). In contrast to the observation that the addition of extra purines inhibited the upregulation of these genes in the WT strain, supplementing guanine or hypoxanthine to serum or M9 medium did not inhibit the upregulation in the ΔpurR strain (Fig 4A & 4B, blue columns), suggesting that upregulation of purine biosynthesis genes in response to purine scarcity was mediated by PurR. In addition, expression analysis in purR-OE strain showed that purR overexpression resulted in repression of purine biosynthesis genes and supplementation of purines could further enhance the suppressing effect (Fig 4A & 4B, teal columns).

Given the critical role of de novo nucleotide biosynthesis genes in ExPEC pathogenesis, it was next examined whether their regulator PurR was also involved in virulence. Using competitive infection assays, we compared the relative in vivo fitness of the ΔpurR and purR-OE strains against the WT strain. The results showed that ΔpurR strain demonstrated significantly greater competitive fitness in the liver, spleen, and blood (competitive index > 1, P < 0.05) (Fig 5A). In contrast, the purR-OE strain exhibited markedly reduced fitness in all four tissues tested (competitive index < 1, P < 0.05) (Fig 5A). To further delineate the role of purR in the virulence of ExPEC PCN033, we conducted individual mouse infection experiments with each of the WT, ΔpurR, and purR-OE strains using identical infection doses. Mouse survival assay results showed that following a lethal dose infection (6 × 10⁵ CFU, intraperitoneal injection), mice infected with the ΔpurR strain exhibited reduced survival compared to WT-infection mice (Fig 5B). In contrast, infection with the purR-OE strain resulted in a trend to increased survival relative to the WT strain (Fig 5B). The percent survival showed a statistically significant difference between the ΔpurR and purR-OE groups (P = 0.026). Bacterial colonization was further assessed by measuring bacterial burdens in various organ tissues at specific timepoints post-infection following infection using a sub-lethal dose (2 × 10⁵ CFU, intraperitoneal injection). The results showed that at 24 hpi, mice infected with the ΔpurR strain exhibited significantly higher bacterial loads in the blood, brain, liver, and spleen compared with those infected with the WT strain (Fig 5C). However, the purR-OE strain displayed significantly reduced colonization in the blood (12 and 36 hpi), brain (36 hpi), liver (12 hpi), and spleen (12, 24, and 36 hpi). Collectively, these results demonstrate that PurR plays a crucial role in ExPEC pathogenesis.

Download:

Fig 5. PurR contributes to in vivo fitness of ExPEC.

A. Competitive infection assays. Cells of ΔpurR or purR-OE strains were mixed with ExPEC PCN033 at a 1:1 ratio, and the mixture containing a total of 2 × 10⁵ CFU was intraperitoneally injected into mice. At twelve hours post-infection, mice were humanely euthanized, and bacterial burden in tissue samples was quantified for each strain. The competitive index (CI) was calculated by dividing the ratio of the two strains’ loads in the tissues by their corresponding ratio in the inoculum. Statistical analysis was performed using Student’s t-test by comparing the CI of the indicated strain (ΔpurR or purR-OE) with that of the WT strain. Significance levels were defined as ns (not significant), P < 0.05 (*), P < 0.01 (**), and P < 0.001 (***). B. Mouse survival assays. 6 × 10⁵ CFU cells of the mid-log phase WT, ΔpurR, or purR-OE strains were used to intraperitoneally inject mice, respectively. Survival of each group was recorded every day. n = 8. Statistical differences were examined using the Gehan-Breslow-Wilcoxon test, and * indicates P < 0.05. C. In vivo colonization assays. 2 × 10⁵ CFU cells of the mid-log phase WT, ΔpurR, or purR-OE strains were used to infect mice via intraperitoneal injection, respectively. Mice from each group were euthanized at 12, 24, and 36 hpi, and the blood, brain, liver, and spleen samples were collected. The tissues were homogenized, diluted with sterile saline, and plated on LA plates. Colonies were counted after overnight incubation. Statistical significance was assessed using one-way ANOVA. Significance levels were defined as ns (not significant), P < 0.05 (*), P < 0.01 (**), and P < 0.001 (***).

https://doi.org/10.1371/journal.ppat.1013889.g005

Purines modulate the binding of PurR to its target genes

It was next investigated how the de novo purine biosynthesis genes of ExPEC are dynamically regulated during infection. Quantitative measurement of intracellular guanine and hypoxanthine concentrations in ExPEC using ultra performance liquid chromatography (UPLC) revealed significantly lower levels of both purines when the bacteria were incubated in serum compared to LB medium (Fig 6A). To study the interaction between PurR and guanine or hypoxanthine, we performed protein-ligand docking using the state-of-the-art deep-learning approach AlphaFold3. The predicted interface TM (ipTM) scores for both the PurR–guanine and PurR–hypoxanthine complexes were 0.95, indicating high-confidence interactions. (Fig 6B). EMSA analysis of PurR binding to the promoter region of its target gene purE showed concentration-dependent band shifts, while no band shifts were observed when incubating with an unrelated control fragment, confirming PurR-purE promoter interaction (Fig 6C). Notably, at suboptimal PurR concentrations that did not show purE promoter binding, the addition of guanine or hypoxanthine enhanced PurR-purE promoter complex formation (Fig 6D). To further confirm the influence of purine on target binding, PurR_mut, a PurR variant harboring point mutations (Y73A, R190A, T192A) in its substrate-binding pocket, was purified. EMSA results showed that PurR_mut retained the ability to bind the purE promoter. However, unlike wild-type PurR, the addition of guanine or hypoxanthine did not enhance binding. These results demonstrate that guanine and hypoxanthine increase the binding affinity of PurR to its target DNA.

Download:

Fig 6. Purine precursors influence the binding affinity of PurR to its target.

A. Quantification of intracellular purine precursors. ExPEC PCN033 was cultured to mid-log phase in either mouse serum or LB medium. Intracellular metabolites were extracted, and the concentrations of guanine and hypoxanthine were quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS). B. Molecular docking of PurR with guanine and hypoxanthine. The three-dimensional structures of PurR-guanine and PurR-hypoxanthine complexes, along with their ipTM and pTM scores, were predicted using a locally implemented AlphaFold3 server. The PurR protein is depicted in blue, while the ligands (guanine or hypoxanthine) are shown in red. The residues in the binding pocket are shown in green. C & E. Electrophoretic mobility shift assay (EMSA) analysis of PurR binding to the purE promoter region. Purified His-tagged PurR (C) or PurR_mut (E) at various concentrations was incubated with the purE promoter DNA fragment in binding buffer at room temperature for 30 minutes. The reaction mixtures were separated on 6% native polyacrylamide gels, stained with GelRed, and visualized using a gel imaging system. D & F. Effect of guanine and hypoxanthine on PurR-DNA binding. PurR (D) or PurR_mut (F) at a non-binding concentration (0.1 ng/μL) was incubated with the purE promoter region in the presence or absence of varying concentrations of guanine (Gua) or hypoxanthine (Hyp). The binding reactions were electrophoresed on 6% native polyacrylamide gels, stained with GelRed, and analyzed using a gel imaging system.

https://doi.org/10.1371/journal.ppat.1013889.g006

Discussion

ExPEC is well-known for its rapid proliferation within the host, leading to systemic infections with high mortality rates. The bloodstream serves as a critical defense barrier, eliminating invading pathogens through immune mechanisms (including immune cells and the complement system) and nutrient limitation [26]. A hallmark of ExPEC pathogenesis is its ability to overcome these restrictions and multiply in the blood, facilitating dissemination throughout the host [27–29]. Therefore, identifying genes essential for serum growth is crucial for elucidating the mechanism of ExPEC pathogenesis and discovering novel antimicrobial drug targets. Through using Tn screening, 18 serum growth-related genes were identified. In addition to the genes involved in nucleotide biosynthesis, rffG, wecA, rfbA, and gne form another functionally enriched group involved in lipopolysaccharides or extracellular polysaccharides biosynthesis. Disruption of these genes may compromise cell envelope integrity. Studies have reported that impairment of bacterial surface polysaccharides reduced serum survival by decreasing complement killing resistance as well as pathogenicity [26,28,30]. Several amino acid metabolism genes were also identified, including aroA, dadA, sdaA, and pepQ. Among these, aroA is responsible for the synthesis of aromatic amino acids, which is a well-characterized virulence-related gene of several bacterial pathogens and has been used as a live vaccine candidate gene [31]. The others are involved in amino acid utilization, with the deficiency of dadA or sdaA having been reported to influence cell wall synthesis, potentially impairing the stress resistance [32,33]. alx and zntA encode two ion transporters related to manganese and zinc transport, respectively [34,35]. Disruption of the gene impairs serum growth, indicating the importance of maintaining cytoplasmic ion pools for the in vivo fitness of ExPEC.

Our results demonstrate that de novo nucleotide biosynthesis genes are not only critical for serum growth but also essential for the full virulence of ExPEC in an animal model, confirming their crucial role in ExPEC pathogenesis, which aligns with previous studies [19,36]. We further revealed that disruption of the de novo purine biosynthesis pathway did not affect the in vitro stress response capability nor adhesion to host cells, but impaired proliferation in host cells (Fig 2). These findings indicate that de novo nucleotide biosynthesis enables ExPEC to overcome the nutrient limitations within the host, thereby promoting its growth in vivo. Notably, disruption of these genes did not impair ExPEC growth in rich medium but nearly abolished the growth within the host. Therefore, they present promising drug targets for developing antimicrobials with minimal selective pressure, as these inhibitors would only exert antimicrobial activity under specific conditions, such as during host infection. A recent study identified a small-molecule inhibitor targeting the de novo purine biosynthesis protein PurF in Mycobacterium tuberculosis, which demonstrated potent bactericidal activity both in vitro and in vivo [37].

One limitation of this study is that although both purine and pyrimidine biosynthesis pathways were identified in our Tn mutagenesis screening, the focus remained primarily on the purine biosynthesis pathway. In fact, as shown in Table 1, two de novo pyrimidine biosynthesis genes, pyrC and carB, were identified as critical for ExPEC growth in serum, suggesting their potential role in bacterial pathogenesis. This finding aligns with a previous study that also identified the requirement of both purine and pyrimidine biosynthesis for E. coli growth in human blood [38]. We further examined the regulatory mechanism of purine biosynthesis mediated by PurR. However, the regulation of pyrimidine biosynthesis was not dissected in this study, although our RNA-seq data also showed significant upregulation of this pathway upon incubation in serum (Fig 3). Previous studies have suggested that the regulatory mechanisms governing pyrimidine biosynthesis are often far more intricate, involving complex strategies such as attenuation control, transcription start site switching, and reiterative transcription initiation [39]. The detailed regulation of pyrimidine biosynthesis in response to the host environment, and its exact role in bacterial pathogenesis, represents a significant and complex area of research that warrants dedicated future investigation.

Apart from the critical role of the de novo pathway in nucleotide biosynthesis, the vital role of salvage pathways has also been previously reported for the pathogenesis of UPEC [40]. Specifically, Ma et al. revealed that salvage pathways for purine synthesis could support the optimal growth of UPEC in urine. In our Tn screening, no genes involved in the salvage pathways of nucleotide biosynthesis were identified. This discrepancy may be explained by differences in nutrient availability between the two host niches: urine is relatively rich in free purines and nucleobases but poor in carbon sources, whereas serum contains abundant glucose and amino acids yet extremely low levels of free nucleotides. Consequently, ExPEC appears to adaptively switch its nucleotide acquisition strategy by favoring salvage in urine and activating de novo synthesis in blood. This reflects the metabolic flexibility of ExPEC in adapting to the host environment, which contributes to its broad disease spectrum.

Another important finding of this study is that de novo nucleotide biosynthesis genes show significant upregulation during serum incubation or ExPEC infection (Fig 3). Notably, the upregulation of purine biosynthesis is regulated by the transcriptional repressor PurR. Deletion of purR relieved this suppression, enhancing the in vivo fitness of ExPEC, suggesting that dynamic regulation of nucleotide biosynthesis plays a crucial role in ExPEC pathogenesis. Further data demonstrate that serum incubation caused decreased concentration of purines in ExPEC cells, and biochemical analysis showed that purine levels influence PurR’s binding affinity to its target DNA.

ExPEC employs both the de novo pathway and the salvage pathway for nucleotide biosynthesis. Disruption of the de novo pathway does not affect growth in rich medium (Fig 1), indicating that when the free nucleotides are abundant, ExPEC primarily uses the salvage pathway, making the de novo pathway non-essential. However, when environmental free nucleotides are scarce, such as during serum incubation or host infection, intracellular purine levels in bacteria decline. This reduces the binding of purines (e.g., guanine and hypoxanthine) to the repressor PurR, weakening PurR’s interaction with its target genes, primarily those involved in nucleotide biosynthesis. As a result, PurR-mediated repression of the de novo nucleotide biosynthesis pathway is relieved, leading to its upregulation. This allows ExPEC to synthesize nucleotides using the relatively abundant sugars and amino acids available in blood, thereby circumventing extracellular nucleotide limitation and supporting robust proliferation in the bloodstream. Thus, our findings reveal a pathogenic mechanism whereby ExPEC dynamically regulates nucleotide biosynthesis in response to host nucleotide limitation to facilitate its infection.

Materials and methods

Ethics statement

All animal housing and experimental procedures were approved by the Institutional Animal Care and Use Committee of the Animal Center of Huazhong Agricultural University (approval number HZAUMO-2025–0243).

Bacterial strains and culture conditions

All E. coli strains used in this study are listed in S1 Table. The wild-type ExPEC strain PCN033 is a highly virulent and multidrug-resistant strain, and its murine model of systemic infection has been well established [25,41]. Gene deletion mutants of ExPEC PCN033 were constructed by allelic exchange using the suicide vector pRE112 as described previously [42]. Gene complementation was achieved by introducing a pCDF-derived recombinant plasmid containing the indicated gene, including its promoter region, into the respective deletion mutant. PurR overexpression was achieved by introducing the plasmid pCDF-J23110-PurRhis into the ExPEC PCN033 strain to constitutively express PurR, resulting in the purR-OE strain. All the E. coli strains were grown in LB or LB-agar (LA) medium at 37°C with shaking, and antibiotics were used when appropriate during bacterial culture.

Transposon-directed screening of genes essential for serum survival

Tn mutants of ExPEC PCN033 were generated using a Himar1 mariner-based transposon mutagenesis approach established in our previous study [25]. To screen Tn mutants required for growth in the serum, the mid-log phase bacterial culture of the individual Tn mutant was diluted 100-fold (~5 × 10⁴ CFU) into fresh mouse serum (purchased from Oumarsi (Shanghai) Biotechnology Co., Ltd., China; Cat# OMHD-E0069), followed by incubation at 37°C for ten hours. ExPEC PCN033 was used as a positive control that showed robust growth, and E. coli MC4100, a commensal strain, was used as a negative control that did not grow in the serum. Optical density at the wavelength of 600 nm (OD_{600 nm}) was measured to evaluate bacterial growth, and the growth ratio was calculated as OD_{600 nm} of Tn mutant divided by the OD_{600 nm} of ExPEC PCN033 strain. Mutants showing significantly reduced growth in serum were selected for Tn insertion site identification using a two-round nested PCR followed by Sanger DNA sequencing as described previously [25]. Clusters of Orthologous Groups (COG) annotation of the genes was performed using eggNOG-mapper [43].

RNA-sequencing and data analysis

To determine the transcriptional response of ExPEC upon transition from rich medium to serum, ExPEC PCN033 cells were cultured in LB medium to the mid-log phase. The cells were subsequently washed three times with sterile saline and inoculated into fresh mouse serum, giving an initial concentration of 10⁸ CFU/ml, followed by incubation for one hour at 37°C. Both groups contained three biological replicates. The cells were then harvested, and total RNA was extracted using the RNeasy Kit (Cat# 4992858, Tiangen) with on-column DNase I treatment. RNA quality was assessed using an Agilent 2100 Bioanalyzer. rRNA was depleted using the Ribo-Zero kit (Cat# 20040529, Illumina), and strand-specific libraries were prepared for sequencing on an Illumina NovaSeq platform. Raw reads were trimmed and mapped to the ExPEC PCN033 reference genome using HISAT2 [44]. Differentially expressed genes were identified using DESeq2 [45] with thresholds of |log₂ fold change| > 1 and FDR < 0.05. Kyoto Encyclopedia of Genes and Genomes (KEGG) annotation and enrichment were analyzed using clusterProfiler [46].

Animal experiments

Animal infection experiments were conducted using four-week-old female specific pathogen-free (SPF) Kunming (KM) mice. In the mouse survival assay, a lethal dose of 6 × 10⁵ CFU of mid-log phase ExPEC PCN033 or its derivative strains was used to infect mice via intraperitoneal injection. Survival was monitored daily. To assess bacterial colonization in vivo, mice were intraperitoneally injected with 2 × 10⁵ CFU of ExPEC PCN033 or its derivatives. At 12, 24, and 36 hours post-infection (hpi), the mice were euthanized, and organ samples (including liver, spleen, blood, and brain) were collected. The tissues were homogenized in sterile saline, serially diluted, and then plated onto LB agar for CFU enumeration. Competitive infection assays were performed to compare the in vivo fitness differences between the two strains, as previously described [25]. Briefly, a 1:1 mixture of mid-log phase cells of two strains containing a total of 2 × 10⁵ CFU was intraperitoneally injected into mice. The mice were euthanized at 12 hpi, followed by bacterial burden quantification of each strain in the tissue samples. The competitive index was calculated by dividing the ratio of the two strains’ loads in the tissues by their corresponding ratio in the inoculum.

Cell adhesion and intracellular survival assay

To assess cell adhesion, cells of the porcine kidney cell line PK-15 were seeded in 24-well plates and cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% heat-inactivated fetal bovine serum. The cells were infected with the mid-log phase cells of EXPEC PCN033 and its mutant derivatives in 24-well plates at a multiplicity of infection (MOI) of 10:1 and incubated at 37°C with 5% CO₂ for one hour. The cell culture was then washed twice with sterile PBS, and sterile water was added, which was incubated at 4°C for 1 hour for cell lysis. The lysate was serially diluted and applied to LB agar plates for bacterial counting [25]. For the intracellular survival assay, the bacterial cells were mixed with RAW264.7 cells with an MOI of 10:1, followed by incubation at 37°C for one hour. Then, the cells were washed twice with sterile PBS, and the unphagocytized bacterial cells were killed by incubation with PBS containing chloramphenicol (final concentration 50 μg/ml). The cells were continued to be cultured in fresh DMEM. After two hours of incubation, macrophages were lysed in the same way as above for bacterial counting [19,25].

Quantitative Real-Time PCR (RT-qPCR) analysis

The mid-log phase cells of EXPEC PCN033 or its derivatives were incubated at 37°C under different conditions (serum or M9 medium, with or without supplementing guanine or hypoxanthine) for one hour. Subsequently, the bacterial cells were harvested by centrifugation, and total RNA was extracted using the RNeasy Kit (Cat# 4992858, Tiangen) with on-column DNase I treatment. RNA purity and concentration were assessed spectrophotometrically with A260/A280 ratios of 1.8 – 2.0. cDNA was synthesized from 1 μg RNA using the PrimeScript RT Reagent Kit (Cat# RR036A, Takara, Japan). Quantitative PCR was performed in triplicate using qPCR Mix (Cat# RR430A, Takara, Japan) on a CFX96 Real-Time PCR System (Bio-Rad, USA). The housekeeping gapA gene served as the internal reference, and relative gene expression was calculated via the 2^−ΔΔCt method.

Protein-ligand docking with Alphafold3

Docking of PurR of ExPEC with guanine or hypoxanthine was performed with a locally installed Alphafold3 [47]. The predicted complex structure was visualized using ChimeraX [48].

Quantitation of intracellular concentrations of purines

ExPEC PCN033 was incubated in mouse serum or LB to the mid-log phase. Bacterial cells were harvested, washed twice with ice-cold PBS. Intracellular metabolites were extracted using 80% methanol at -80°C and dried under vacuum. Metabolite concentrations were quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS) with an Agilent 1290 UHPLC coupled to a 6470 triple quadrupole mass spectrometer.

Electrophoretic mobility shift assay

Electrophoretic mobility shift assay (EMSA) was performed as described previously [49]. His-tagged PurR or PurR containing point mutations was expressed using the pET28a vector system and purified using nickel-ion affinity chromatography. The purified PurR protein with varied concentrations was incubated with the DNA fragment of the promoter region of the target genes or an unrelated fragment as a negative control in binding buffer (0.3 M NaCl and 0.05 M NaH₂PO₄) at room temperature for 30 min in the absence or presence of different concentrations of guanine or hypoxanthine. Binding reactions were resolved on 6% native polyacrylamide gels, followed by staining with Gelred and detection using a gel imaging system.

Statistical analysis

Data are presented as the mean ± standard error of the mean (SEM). Student’s t-test was used to determine statistical significance between two groups, while one-way analysis of variance (ANOVA) was used for comparisons among multiple groups. Survival curves were analyzed using the Gehan-Breslow-Wilcoxon test. All statistical analyses were performed using GraphPad Prism 8 software. P values < 0.05, < 0.01, < 0.001, and < 0.0001 were considered statistically significant and are denoted by *, **, ***, and ****, respectively.

Supporting information

S1 Fig. Growth curves of ExPEC and commensal E. coli in serum.

Overnight cultures of ExPEC PCN033 strain and E. coli MC4100 strain were inoculated at a 1:100 ratio into fresh mouse serum. The OD_{600 nm} was measured hourly.

https://doi.org/10.1371/journal.ppat.1013889.s001

(TIF)

S2 Fig. Growth curves of deletion mutants and their complemented strains of de novo nucleotide biosynthesis genes in serum.

Overnight cultures of each strain were inoculated 1:100 into fresh mouse serum. OD_{600 nm} was measured every two hours.

https://doi.org/10.1371/journal.ppat.1013889.s002

(TIF)

S3 Fig. Western blotting analysis of PurR expression.

ExPEC strain PCN033 or PCN033 carrying pCDF-J23110-PurRhis plasmid (purR-OE) was grown to the mid-log phase in LB medium. Cells were harvested, and the whole cell lysate and lysate supernatant were prepared. The samples were subjected to SDS-PAGE followed by Western blotting analysis using an anti-His monoclonal antibody as the primary antibody.

https://doi.org/10.1371/journal.ppat.1013889.s003

(TIF)

S1 Table. Bacterial strains used in this study.

https://doi.org/10.1371/journal.ppat.1013889.s004

(DOCX)

References

1. Moulin-Schouleur M, Répérant M, Laurent S, Brée A, Mignon-Grasteau S, Germon P, et al. Extraintestinal pathogenic Escherichia coli strains of avian and human origin: link between phylogenetic relationships and common virulence patterns. J Clin Microbiol. 2007;45(10):3366–76. pmid:17652485
- View Article
- PubMed/NCBI
- Google Scholar
2. Poolman JT, Wacker M. Extraintestinal Pathogenic Escherichia coli, a Common Human Pathogen: Challenges for Vaccine Development and Progress in the Field. J Infect Dis. 2016;213(1):6–13. pmid:26333944
- View Article
- PubMed/NCBI
- Google Scholar
3. Dale AP, Woodford N. Extra-intestinal pathogenic Escherichia coli (ExPEC): Disease, carriage and clones. J Infect. 2015;71(6):615–26. pmid:26409905
- View Article
- PubMed/NCBI
- Google Scholar
4. Vila J, Sáez-López E, Johnson JR, Römling U, Dobrindt U, Cantón R, et al. Escherichia coli: an old friend with new tidings. FEMS Microbiol Rev. 2016;40(4):437–63. pmid:28201713
- View Article
- PubMed/NCBI
- Google Scholar
5. Zhou Y, Zhou Z, Zheng L, Gong Z, Li Y, Jin Y, et al. Urinary Tract Infections Caused by Uropathogenic Escherichia coli: Mechanisms of Infection and Treatment Options. Int J Mol Sci. 2023;24(13):10537. pmid:37445714
- View Article
- PubMed/NCBI
- Google Scholar
6. Li X, Hu H, Zhu Y, Wang T, Lu Y, Wang X, et al. Population structure and antibiotic resistance of swine extraintestinal pathogenic Escherichia coli from China. Nat Commun. 2024;15(1):5811. pmid:38987310
- View Article
- PubMed/NCBI
- Google Scholar
7. Pitout JDD. Extraintestinal Pathogenic Escherichia coli: A Combination of Virulence with Antibiotic Resistance. Front Microbiol. 2012;3:9. pmid:22294983
- View Article
- PubMed/NCBI
- Google Scholar
8. Qiu L, Chirman D, Clark JR, Xing Y, Hernandez Santos H, Vaughan EE, et al. Vaccines against extraintestinal pathogenic Escherichia coli (ExPEC): progress and challenges. Gut Microbes. 2024;16(1):2359691. pmid:38825856
- View Article
- PubMed/NCBI
- Google Scholar
9. Hasso-Agopsowicz M, Hwang A, Hollm-Delgado M-G, Umbelino-Walker I, Karron RA, Rao R, et al. Identifying WHO global priority endemic pathogens for vaccine research and development (R&D) using multi-criteria decision analysis (MCDA): an objective of the Immunization Agenda 2030. EBioMedicine. 2024;110:105424. pmid:39500705
- View Article
- PubMed/NCBI
- Google Scholar
10. Hunt JM. Shiga toxin-producing Escherichia coli (STEC). Clin Lab Med. 2010;30(1):21–45. pmid:20513540
- View Article
- PubMed/NCBI
- Google Scholar
11. Sheikh A, Tumala B, Vickers TJ, Martin JC, Rosa BA, Sabui S, et al. Enterotoxigenic Escherichia coli heat-labile toxin drives enteropathic changes in small intestinal epithelia. Nat Commun. 2022;13(1):6886. pmid:36371425
- View Article
- PubMed/NCBI
- Google Scholar
12. Welch RA. Uropathogenic Escherichia coli-Associated Exotoxins. Microbiol Spectr. 2016;4(3):10.1128/microbiolspec.UTI-0011–2012. pmid:27337488
- View Article
- PubMed/NCBI
- Google Scholar
13. Biran D, Ron EZ. Extraintestinal Pathogenic Escherichia coli. Curr Top Microbiol Immunol. 2018;416:149–61. pmid:30046982
- View Article
- PubMed/NCBI
- Google Scholar
14. Royer G, Clermont O, Marin J, Condamine B, Dion S, Blanquart F, et al. Epistatic interactions between the high pathogenicity island and other iron uptake systems shape Escherichia coli extra-intestinal virulence. Nat Commun. 2023;14(1):3667. pmid:37339949
- View Article
- PubMed/NCBI
- Google Scholar
15. Huja S, Oren Y, Biran D, Meyer S, Dobrindt U, Bernhard J, et al. Fur is the master regulator of the extraintestinal pathogenic Escherichia coli response to serum. mBio. 2014;5(4):e01460-14. pmid:25118243
- View Article
- PubMed/NCBI
- Google Scholar
16. Mann R, Mediati DG, Duggin IG, Harry EJ, Bottomley AL. Metabolic Adaptations of Uropathogenic E. coli in the Urinary Tract. Front Cell Infect Microbiol. 2017;7:241. pmid:28642845
- View Article
- PubMed/NCBI
- Google Scholar
17. Goncheva MI, Chin D, Heinrichs DE. Nucleotide biosynthesis: the base of bacterial pathogenesis. Trends Microbiol. 2022;30(8):793–804. pmid:35074276
- View Article
- PubMed/NCBI
- Google Scholar
18. Nogami H, Urist MR. The classic : a morphogenetic matrix for differentiation of cartilage in tissue culture. Clin Orthop Relat Res. 2009;467(12):3063–7. pmid:19727988
- View Article
- PubMed/NCBI
- Google Scholar
19. Shaffer CL, Zhang EW, Dudley AG, Dixon BREA, Guckes KR, Breland EJ, et al. Purine Biosynthesis Metabolically Constrains Intracellular Survival of Uropathogenic Escherichia coli. Infect Immun. 2016;85(1):e00471-16. pmid:27795353
- View Article
- PubMed/NCBI
- Google Scholar
20. Kofoed EM, Yan D, Katakam AK, Reichelt M, Lin B, Kim J, et al. De Novo Guanine Biosynthesis but Not the Riboswitch-Regulated Purine Salvage Pathway Is Required for Staphylococcus aureus Infection In Vivo. J Bacteriol. 2016;198(14):2001–15. pmid:27161118
- View Article
- PubMed/NCBI
- Google Scholar
21. Cho B-K, Federowicz SA, Embree M, Park Y-S, Kim D, Palsson BØ. The PurR regulon in Escherichia coli K-12 MG1655. Nucleic Acids Res. 2011;39(15):6456–64. pmid:21572102
- View Article
- PubMed/NCBI
- Google Scholar
22. Goncheva MI, Flannagan RS, Heinrichs DE. De Novo Purine Biosynthesis Is Required for Intracellular Growth of Staphylococcus aureus and for the Hypervirulence Phenotype of a purR Mutant. Infect Immun. 2020;88(5):e00104-20. pmid:32094249
- View Article
- PubMed/NCBI
- Google Scholar
23. Andersen-Civil AIS, Ahmed S, Guerra PR, Andersen TE, Hounmanou YMG, Olsen JE, et al. The impact of inactivation of the purine biosynthesis genes, purN and purT, on growth and virulence in uropathogenic E. coli. Mol Biol Rep. 2018;45(6):2707–16. pmid:30377949
- View Article
- PubMed/NCBI
- Google Scholar
24. Eberly AR, Beebout CJ, Carmen Tong CM, Van Horn GT, Green HD, Fitzgerald MJ, et al. Defining a Molecular Signature for Uropathogenic versus Urocolonizing Escherichia coli: The Status of the Field and New Clinical Opportunities. J Mol Biol. 2020;432(4):786–804. pmid:31794727
- View Article
- PubMed/NCBI
- Google Scholar
25. Yin F, Hu Y, Bu Z, Liu Y, Zhang H, Hu Y, et al. Genome-wide identification of genes critical for in vivo fitness of multi-drug resistant porcine extraintestinal pathogenic Escherichia coli by transposon-directed insertion site sequencing using a mouse infection model. Virulence. 2023;14(1):2158708. pmid:36537189
- View Article
- PubMed/NCBI
- Google Scholar
26. Miajlovic H, Smith SG. Bacterial self-defence: how Escherichia coli evades serum killing. FEMS Microbiol Lett. 2014;354(1):1–9. pmid:24617921
- View Article
- PubMed/NCBI
- Google Scholar
27. Buckles EL, Wang X, Lane MC, Lockatell CV, Johnson DE, Rasko DA, et al. Role of the K2 capsule in Escherichia coli urinary tract infection and serum resistance. J Infect Dis. 2009;199(11):1689–97. pmid:19432551
- View Article
- PubMed/NCBI
- Google Scholar
28. McGarry N, Roe D, Smith SGJ. Synergy between Group 2 capsules and lipopolysaccharide underpins serum resistance in extra-intestinal pathogenic Escherichia coli. Microbiology (Reading). 2024;170(8):001493. pmid:39177453
- View Article
- PubMed/NCBI
- Google Scholar
29. Miajlovic H, Cooke NM, Moran GP, Rogers TRF, Smith SG. Response of extraintestinal pathogenic Escherichia coli to human serum reveals a protective role for Rcs-regulated exopolysaccharide colanic acid. Infect Immun. 2014;82(1):298–305. pmid:24166954
- View Article
- PubMed/NCBI
- Google Scholar
30. Bain W, Ahn B, Peñaloza HF, McElheny CL, Tolman N, van der Geest R, et al. In Vivo Evolution of a Klebsiella pneumoniae Capsule Defect With wcaJ Mutation Promotes Complement-Mediated Opsonophagocytosis During Recurrent Infection. J Infect Dis. 2024;230(1):209–20. pmid:39052750
- View Article
- PubMed/NCBI
- Google Scholar
31. Galal HM, Abdrabou MI, Faraag AHI, Mah CK, Tawfek AM. Evaluation of commercially available aroA delated gene E. coli O78 vaccine in commercial broiler chickens under Middle East simulating field conditions. Sci Rep. 2021;11(1):1938. pmid:33479449
- View Article
- PubMed/NCBI
- Google Scholar
32. Zhang X, El-Hajj ZW, Newman E. Deficiency in L-serine deaminase interferes with one-carbon metabolism and cell wall synthesis in Escherichia coli K-12. J Bacteriol. 2010;192(20):5515–25. pmid:20729359
- View Article
- PubMed/NCBI
- Google Scholar
33. Trivedi RR, Crooks JA, Auer GK, Pendry J, Foik IP, Siryaporn A, et al. Mechanical Genomic Studies Reveal the Role of d-Alanine Metabolism in Pseudomonas aeruginosa Cell Stiffness. mBio. 2018;9(5):e01340-18. pmid:30206169
- View Article
- PubMed/NCBI
- Google Scholar
34. Sharma R, Mishanina TV. A riboswitch-controlled TerC family transporter Alx tunes intracellular manganese concentration in Escherichia coli at alkaline pH. J Bacteriol. 2024;206(7):e0016824. pmid:38869303
- View Article
- PubMed/NCBI
- Google Scholar
35. Zheng C, Zhai Y, Qiu J, Wang M, Xu Z, Chen X, et al. ZntA maintains zinc and cadmium homeostasis and promotes oxidative stress resistance and virulence in Vibrio parahaemolyticus. Gut Microbes. 2024;16(1):2327377. pmid:38466137
- View Article
- PubMed/NCBI
- Google Scholar
36. Ma J, Cheng Z, Bai Q, Zhao K, Pan Z, Yao H. Screening virulence factors of porcine extraintestinal pathogenic Escherichia coli (an emerging pathotype) required for optimal growth in swine blood. Transbound Emerg Dis. 2021;68(4):2005–16. pmid:32969570
- View Article
- PubMed/NCBI
- Google Scholar
37. Lamprecht DA, Wall RJ, Leemans A, Truebody B, Sprangers J, Fiogbe P, et al. Targeting de novo purine biosynthesis for tuberculosis treatment. Nature. 2025;644(8075):214–20. pmid:40533558
- View Article
- PubMed/NCBI
- Google Scholar
38. Samant S, Lee H, Ghassemi M, Chen J, Cook JL, Mankin AS, et al. Nucleotide biosynthesis is critical for growth of bacteria in human blood. PLoS Pathog. 2008;4(2):e37. pmid:18282099
- View Article
- PubMed/NCBI
- Google Scholar
39. Turnbough CL Jr, Switzer RL. Regulation of pyrimidine biosynthetic gene expression in bacteria: repression without repressors. Microbiol Mol Biol Rev. 2008;72(2):266–300, table of contents. pmid:18535147
- View Article
- PubMed/NCBI
- Google Scholar
40. Ma J, Cai X, Bao Y, Yao H, Li G. Uropathogenic Escherichia coli preferentially utilize metabolites in urine for nucleotide biosynthesis through salvage pathways. Int J Med Microbiol. 2018;308(8):990–9. pmid:30145133
- View Article
- PubMed/NCBI
- Google Scholar
41. Liu C, Zheng H, Yang M, Xu Z, Wang X, Wei L, et al. Genome analysis and in vivo virulence of porcine extraintestinal pathogenic Escherichia coli strain PCN033. BMC Genomics. 2015;16(1):717. pmid:26391348
- View Article
- PubMed/NCBI
- Google Scholar
42. Liu J, Yin F, Liu T, Li S, Tan C, Li L, et al. The Tat system and its dependent cell division proteins are critical for virulence of extra-intestinal pathogenic Escherichia coli. Virulence. 2020;11(1):1279–92. pmid:32962530
- View Article
- PubMed/NCBI
- Google Scholar
43. Cantalapiedra CP, Hernández-Plaza A, Letunic I, Bork P, Huerta-Cepas J. eggNOG-mapper v2: Functional Annotation, Orthology Assignments, and Domain Prediction at the Metagenomic Scale. Mol Biol Evol. 2021;38(12):5825–9. pmid:34597405
- View Article
- PubMed/NCBI
- Google Scholar
44. Kim D, Paggi JM, Park C, Bennett C, Salzberg SL. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol. 2019;37(8):907–15. pmid:31375807
- View Article
- PubMed/NCBI
- Google Scholar
45. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. pmid:25516281
- View Article
- PubMed/NCBI
- Google Scholar
46. Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–7. pmid:22455463
- View Article
- PubMed/NCBI
- Google Scholar
47. Abramson J, Adler J, Dunger J, Evans R, Green T, Pritzel A, et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature. 2024;630(8016):493–500. pmid:38718835
- View Article
- PubMed/NCBI
- Google Scholar
48. Meng EC, Goddard TD, Pettersen EF, Couch GS, Pearson ZJ, Morris JH, et al. UCSF ChimeraX: Tools for structure building and analysis. Protein Sci. 2023;32(11):e4792. pmid:37774136
- View Article
- PubMed/NCBI
- Google Scholar
49. Zhang Q, Huang Q, Fang Q, Li H, Tang H, Zou G, et al. Identification of genes regulated by the two-component system response regulator NarP of Actinobacillus pleuropneumoniae via DNA-affinity-purified sequencing. Microbiol Res. 2020;230:126343. pmid:31539852
- View Article
- PubMed/NCBI
- Google Scholar

[ref1] 1. Moulin-Schouleur M, Répérant M, Laurent S, Brée A, Mignon-Grasteau S, Germon P, et al. Extraintestinal pathogenic Escherichia coli strains of avian and human origin: link between phylogenetic relationships and common virulence patterns. J Clin Microbiol. 2007;45(10):3366–76. pmid:17652485
View Article
PubMed/NCBI
Google Scholar

[2] View Article

[3] PubMed/NCBI

[4] Google Scholar

[ref2] 2. Poolman JT, Wacker M. Extraintestinal Pathogenic Escherichia coli, a Common Human Pathogen: Challenges for Vaccine Development and Progress in the Field. J Infect Dis. 2016;213(1):6–13. pmid:26333944
View Article
PubMed/NCBI
Google Scholar

[6] View Article

[7] PubMed/NCBI

[8] Google Scholar

[ref3] 3. Dale AP, Woodford N. Extra-intestinal pathogenic Escherichia coli (ExPEC): Disease, carriage and clones. J Infect. 2015;71(6):615–26. pmid:26409905
View Article
PubMed/NCBI
Google Scholar

[10] View Article

[11] PubMed/NCBI

[12] Google Scholar

[ref4] 4. Vila J, Sáez-López E, Johnson JR, Römling U, Dobrindt U, Cantón R, et al. Escherichia coli: an old friend with new tidings. FEMS Microbiol Rev. 2016;40(4):437–63. pmid:28201713
View Article
PubMed/NCBI
Google Scholar

[14] View Article

[15] PubMed/NCBI

[16] Google Scholar

[ref5] 5. Zhou Y, Zhou Z, Zheng L, Gong Z, Li Y, Jin Y, et al. Urinary Tract Infections Caused by Uropathogenic Escherichia coli: Mechanisms of Infection and Treatment Options. Int J Mol Sci. 2023;24(13):10537. pmid:37445714
View Article
PubMed/NCBI
Google Scholar

[18] View Article

[19] PubMed/NCBI

[20] Google Scholar

[ref6] 6. Li X, Hu H, Zhu Y, Wang T, Lu Y, Wang X, et al. Population structure and antibiotic resistance of swine extraintestinal pathogenic Escherichia coli from China. Nat Commun. 2024;15(1):5811. pmid:38987310
View Article
PubMed/NCBI
Google Scholar

[22] View Article

[23] PubMed/NCBI

[24] Google Scholar

[ref7] 7. Pitout JDD. Extraintestinal Pathogenic Escherichia coli: A Combination of Virulence with Antibiotic Resistance. Front Microbiol. 2012;3:9. pmid:22294983
View Article
PubMed/NCBI
Google Scholar

[26] View Article

[27] PubMed/NCBI

[28] Google Scholar

[ref8] 8. Qiu L, Chirman D, Clark JR, Xing Y, Hernandez Santos H, Vaughan EE, et al. Vaccines against extraintestinal pathogenic Escherichia coli (ExPEC): progress and challenges. Gut Microbes. 2024;16(1):2359691. pmid:38825856
View Article
PubMed/NCBI
Google Scholar

[30] View Article

[31] PubMed/NCBI

[32] Google Scholar

[ref9] 9. Hasso-Agopsowicz M, Hwang A, Hollm-Delgado M-G, Umbelino-Walker I, Karron RA, Rao R, et al. Identifying WHO global priority endemic pathogens for vaccine research and development (R&D) using multi-criteria decision analysis (MCDA): an objective of the Immunization Agenda 2030. EBioMedicine. 2024;110:105424. pmid:39500705
View Article
PubMed/NCBI
Google Scholar

[34] View Article

[35] PubMed/NCBI

[36] Google Scholar

[ref10] 10. Hunt JM. Shiga toxin-producing Escherichia coli (STEC). Clin Lab Med. 2010;30(1):21–45. pmid:20513540
View Article
PubMed/NCBI
Google Scholar

[38] View Article

[39] PubMed/NCBI

[40] Google Scholar

[ref11] 11. Sheikh A, Tumala B, Vickers TJ, Martin JC, Rosa BA, Sabui S, et al. Enterotoxigenic Escherichia coli heat-labile toxin drives enteropathic changes in small intestinal epithelia. Nat Commun. 2022;13(1):6886. pmid:36371425
View Article
PubMed/NCBI
Google Scholar

[42] View Article

[43] PubMed/NCBI

[44] Google Scholar

[ref12] 12. Welch RA. Uropathogenic Escherichia coli-Associated Exotoxins. Microbiol Spectr. 2016;4(3):10.1128/microbiolspec.UTI-0011–2012. pmid:27337488
View Article
PubMed/NCBI
Google Scholar

[46] View Article

[47] PubMed/NCBI

[48] Google Scholar

[ref13] 13. Biran D, Ron EZ. Extraintestinal Pathogenic Escherichia coli. Curr Top Microbiol Immunol. 2018;416:149–61. pmid:30046982
View Article
PubMed/NCBI
Google Scholar

[50] View Article

[51] PubMed/NCBI

[52] Google Scholar

[ref14] 14. Royer G, Clermont O, Marin J, Condamine B, Dion S, Blanquart F, et al. Epistatic interactions between the high pathogenicity island and other iron uptake systems shape Escherichia coli extra-intestinal virulence. Nat Commun. 2023;14(1):3667. pmid:37339949
View Article
PubMed/NCBI
Google Scholar

[54] View Article

[55] PubMed/NCBI

[56] Google Scholar

[ref15] 15. Huja S, Oren Y, Biran D, Meyer S, Dobrindt U, Bernhard J, et al. Fur is the master regulator of the extraintestinal pathogenic Escherichia coli response to serum. mBio. 2014;5(4):e01460-14. pmid:25118243
View Article
PubMed/NCBI
Google Scholar

[58] View Article

[59] PubMed/NCBI

[60] Google Scholar

[ref16] 16. Mann R, Mediati DG, Duggin IG, Harry EJ, Bottomley AL. Metabolic Adaptations of Uropathogenic E. coli in the Urinary Tract. Front Cell Infect Microbiol. 2017;7:241. pmid:28642845
View Article
PubMed/NCBI
Google Scholar

[62] View Article

[63] PubMed/NCBI

[64] Google Scholar

[ref17] 17. Goncheva MI, Chin D, Heinrichs DE. Nucleotide biosynthesis: the base of bacterial pathogenesis. Trends Microbiol. 2022;30(8):793–804. pmid:35074276
View Article
PubMed/NCBI
Google Scholar

[66] View Article

[67] PubMed/NCBI

[68] Google Scholar

[ref18] 18. Nogami H, Urist MR. The classic : a morphogenetic matrix for differentiation of cartilage in tissue culture. Clin Orthop Relat Res. 2009;467(12):3063–7. pmid:19727988
View Article
PubMed/NCBI
Google Scholar

[70] View Article

[71] PubMed/NCBI

[72] Google Scholar

[ref19] 19. Shaffer CL, Zhang EW, Dudley AG, Dixon BREA, Guckes KR, Breland EJ, et al. Purine Biosynthesis Metabolically Constrains Intracellular Survival of Uropathogenic Escherichia coli. Infect Immun. 2016;85(1):e00471-16. pmid:27795353
View Article
PubMed/NCBI
Google Scholar

[74] View Article

[75] PubMed/NCBI

[76] Google Scholar

[ref20] 20. Kofoed EM, Yan D, Katakam AK, Reichelt M, Lin B, Kim J, et al. De Novo Guanine Biosynthesis but Not the Riboswitch-Regulated Purine Salvage Pathway Is Required for Staphylococcus aureus Infection In Vivo. J Bacteriol. 2016;198(14):2001–15. pmid:27161118
View Article
PubMed/NCBI
Google Scholar

[78] View Article

[79] PubMed/NCBI

[80] Google Scholar

[ref21] 21. Cho B-K, Federowicz SA, Embree M, Park Y-S, Kim D, Palsson BØ. The PurR regulon in Escherichia coli K-12 MG1655. Nucleic Acids Res. 2011;39(15):6456–64. pmid:21572102
View Article
PubMed/NCBI
Google Scholar

[82] View Article

[83] PubMed/NCBI

[84] Google Scholar

[ref22] 22. Goncheva MI, Flannagan RS, Heinrichs DE. De Novo Purine Biosynthesis Is Required for Intracellular Growth of Staphylococcus aureus and for the Hypervirulence Phenotype of a purR Mutant. Infect Immun. 2020;88(5):e00104-20. pmid:32094249
View Article
PubMed/NCBI
Google Scholar

[86] View Article

[87] PubMed/NCBI

[88] Google Scholar

[ref23] 23. Andersen-Civil AIS, Ahmed S, Guerra PR, Andersen TE, Hounmanou YMG, Olsen JE, et al. The impact of inactivation of the purine biosynthesis genes, purN and purT, on growth and virulence in uropathogenic E. coli. Mol Biol Rep. 2018;45(6):2707–16. pmid:30377949
View Article
PubMed/NCBI
Google Scholar

[90] View Article

[91] PubMed/NCBI

[92] Google Scholar

[ref24] 24. Eberly AR, Beebout CJ, Carmen Tong CM, Van Horn GT, Green HD, Fitzgerald MJ, et al. Defining a Molecular Signature for Uropathogenic versus Urocolonizing Escherichia coli: The Status of the Field and New Clinical Opportunities. J Mol Biol. 2020;432(4):786–804. pmid:31794727
View Article
PubMed/NCBI
Google Scholar

[94] View Article

[95] PubMed/NCBI

[96] Google Scholar

[ref25] 25. Yin F, Hu Y, Bu Z, Liu Y, Zhang H, Hu Y, et al. Genome-wide identification of genes critical for in vivo fitness of multi-drug resistant porcine extraintestinal pathogenic Escherichia coli by transposon-directed insertion site sequencing using a mouse infection model. Virulence. 2023;14(1):2158708. pmid:36537189
View Article
PubMed/NCBI
Google Scholar

[98] View Article

[99] PubMed/NCBI

[100] Google Scholar

[ref26] 26. Miajlovic H, Smith SG. Bacterial self-defence: how Escherichia coli evades serum killing. FEMS Microbiol Lett. 2014;354(1):1–9. pmid:24617921
View Article
PubMed/NCBI
Google Scholar

[102] View Article

[103] PubMed/NCBI

[104] Google Scholar

[ref27] 27. Buckles EL, Wang X, Lane MC, Lockatell CV, Johnson DE, Rasko DA, et al. Role of the K2 capsule in Escherichia coli urinary tract infection and serum resistance. J Infect Dis. 2009;199(11):1689–97. pmid:19432551
View Article
PubMed/NCBI
Google Scholar

[106] View Article

[107] PubMed/NCBI

[108] Google Scholar

[ref28] 28. McGarry N, Roe D, Smith SGJ. Synergy between Group 2 capsules and lipopolysaccharide underpins serum resistance in extra-intestinal pathogenic Escherichia coli. Microbiology (Reading). 2024;170(8):001493. pmid:39177453
View Article
PubMed/NCBI
Google Scholar

[110] View Article

[111] PubMed/NCBI

[112] Google Scholar

[ref29] 29. Miajlovic H, Cooke NM, Moran GP, Rogers TRF, Smith SG. Response of extraintestinal pathogenic Escherichia coli to human serum reveals a protective role for Rcs-regulated exopolysaccharide colanic acid. Infect Immun. 2014;82(1):298–305. pmid:24166954
View Article
PubMed/NCBI
Google Scholar

[114] View Article

[115] PubMed/NCBI

[116] Google Scholar

[ref30] 30. Bain W, Ahn B, Peñaloza HF, McElheny CL, Tolman N, van der Geest R, et al. In Vivo Evolution of a Klebsiella pneumoniae Capsule Defect With wcaJ Mutation Promotes Complement-Mediated Opsonophagocytosis During Recurrent Infection. J Infect Dis. 2024;230(1):209–20. pmid:39052750
View Article
PubMed/NCBI
Google Scholar

[118] View Article

[119] PubMed/NCBI

[120] Google Scholar

[ref31] 31. Galal HM, Abdrabou MI, Faraag AHI, Mah CK, Tawfek AM. Evaluation of commercially available aroA delated gene E. coli O78 vaccine in commercial broiler chickens under Middle East simulating field conditions. Sci Rep. 2021;11(1):1938. pmid:33479449
View Article
PubMed/NCBI
Google Scholar

[122] View Article

[123] PubMed/NCBI

[124] Google Scholar

[ref32] 32. Zhang X, El-Hajj ZW, Newman E. Deficiency in L-serine deaminase interferes with one-carbon metabolism and cell wall synthesis in Escherichia coli K-12. J Bacteriol. 2010;192(20):5515–25. pmid:20729359
View Article
PubMed/NCBI
Google Scholar

[126] View Article

[127] PubMed/NCBI

[128] Google Scholar

[ref33] 33. Trivedi RR, Crooks JA, Auer GK, Pendry J, Foik IP, Siryaporn A, et al. Mechanical Genomic Studies Reveal the Role of d-Alanine Metabolism in Pseudomonas aeruginosa Cell Stiffness. mBio. 2018;9(5):e01340-18. pmid:30206169
View Article
PubMed/NCBI
Google Scholar

[130] View Article

[131] PubMed/NCBI

[132] Google Scholar

[ref34] 34. Sharma R, Mishanina TV. A riboswitch-controlled TerC family transporter Alx tunes intracellular manganese concentration in Escherichia coli at alkaline pH. J Bacteriol. 2024;206(7):e0016824. pmid:38869303
View Article
PubMed/NCBI
Google Scholar

[134] View Article

[135] PubMed/NCBI

[136] Google Scholar

[ref35] 35. Zheng C, Zhai Y, Qiu J, Wang M, Xu Z, Chen X, et al. ZntA maintains zinc and cadmium homeostasis and promotes oxidative stress resistance and virulence in Vibrio parahaemolyticus. Gut Microbes. 2024;16(1):2327377. pmid:38466137
View Article
PubMed/NCBI
Google Scholar

[138] View Article

[139] PubMed/NCBI

[140] Google Scholar

[ref36] 36. Ma J, Cheng Z, Bai Q, Zhao K, Pan Z, Yao H. Screening virulence factors of porcine extraintestinal pathogenic Escherichia coli (an emerging pathotype) required for optimal growth in swine blood. Transbound Emerg Dis. 2021;68(4):2005–16. pmid:32969570
View Article
PubMed/NCBI
Google Scholar

[142] View Article

[143] PubMed/NCBI

[144] Google Scholar

[ref37] 37. Lamprecht DA, Wall RJ, Leemans A, Truebody B, Sprangers J, Fiogbe P, et al. Targeting de novo purine biosynthesis for tuberculosis treatment. Nature. 2025;644(8075):214–20. pmid:40533558
View Article
PubMed/NCBI
Google Scholar

[146] View Article

[147] PubMed/NCBI

[148] Google Scholar

[ref38] 38. Samant S, Lee H, Ghassemi M, Chen J, Cook JL, Mankin AS, et al. Nucleotide biosynthesis is critical for growth of bacteria in human blood. PLoS Pathog. 2008;4(2):e37. pmid:18282099
View Article
PubMed/NCBI
Google Scholar

[150] View Article

[151] PubMed/NCBI

[152] Google Scholar

[ref39] 39. Turnbough CL Jr, Switzer RL. Regulation of pyrimidine biosynthetic gene expression in bacteria: repression without repressors. Microbiol Mol Biol Rev. 2008;72(2):266–300, table of contents. pmid:18535147
View Article
PubMed/NCBI
Google Scholar

[154] View Article

[155] PubMed/NCBI

[156] Google Scholar

[ref40] 40. Ma J, Cai X, Bao Y, Yao H, Li G. Uropathogenic Escherichia coli preferentially utilize metabolites in urine for nucleotide biosynthesis through salvage pathways. Int J Med Microbiol. 2018;308(8):990–9. pmid:30145133
View Article
PubMed/NCBI
Google Scholar

[158] View Article

[159] PubMed/NCBI

[160] Google Scholar

[ref41] 41. Liu C, Zheng H, Yang M, Xu Z, Wang X, Wei L, et al. Genome analysis and in vivo virulence of porcine extraintestinal pathogenic Escherichia coli strain PCN033. BMC Genomics. 2015;16(1):717. pmid:26391348
View Article
PubMed/NCBI
Google Scholar

[162] View Article

[163] PubMed/NCBI

[164] Google Scholar

[ref42] 42. Liu J, Yin F, Liu T, Li S, Tan C, Li L, et al. The Tat system and its dependent cell division proteins are critical for virulence of extra-intestinal pathogenic Escherichia coli. Virulence. 2020;11(1):1279–92. pmid:32962530
View Article
PubMed/NCBI
Google Scholar

[166] View Article

[167] PubMed/NCBI

[168] Google Scholar

[ref43] 43. Cantalapiedra CP, Hernández-Plaza A, Letunic I, Bork P, Huerta-Cepas J. eggNOG-mapper v2: Functional Annotation, Orthology Assignments, and Domain Prediction at the Metagenomic Scale. Mol Biol Evol. 2021;38(12):5825–9. pmid:34597405
View Article
PubMed/NCBI
Google Scholar

[170] View Article

[171] PubMed/NCBI

[172] Google Scholar

[ref44] 44. Kim D, Paggi JM, Park C, Bennett C, Salzberg SL. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol. 2019;37(8):907–15. pmid:31375807
View Article
PubMed/NCBI
Google Scholar

[174] View Article

[175] PubMed/NCBI

[176] Google Scholar

[ref45] 45. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. pmid:25516281
View Article
PubMed/NCBI
Google Scholar

[178] View Article

[179] PubMed/NCBI

[180] Google Scholar

[ref46] 46. Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–7. pmid:22455463
View Article
PubMed/NCBI
Google Scholar

[182] View Article

[183] PubMed/NCBI

[184] Google Scholar

[ref47] 47. Abramson J, Adler J, Dunger J, Evans R, Green T, Pritzel A, et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature. 2024;630(8016):493–500. pmid:38718835
View Article
PubMed/NCBI
Google Scholar

[186] View Article

[187] PubMed/NCBI

[188] Google Scholar

[ref48] 48. Meng EC, Goddard TD, Pettersen EF, Couch GS, Pearson ZJ, Morris JH, et al. UCSF ChimeraX: Tools for structure building and analysis. Protein Sci. 2023;32(11):e4792. pmid:37774136
View Article
PubMed/NCBI
Google Scholar

[190] View Article

[191] PubMed/NCBI

[192] Google Scholar

[ref49] 49. Zhang Q, Huang Q, Fang Q, Li H, Tang H, Zou G, et al. Identification of genes regulated by the two-component system response regulator NarP of Actinobacillus pleuropneumoniae via DNA-affinity-purified sequencing. Microbiol Res. 2020;230:126343. pmid:31539852
View Article
PubMed/NCBI
Google Scholar

[194] View Article

[195] PubMed/NCBI

[196] Google Scholar

Figures

Abstract

Author summary

Introduction

Results

Genome-wide screening reveals the essential role of de novo nucleotide biosynthesis genes in ExEPC serum survival

The de novo nucleotide biosynthesis pathway is critical for the virulence of ExPEC

The expression of de novo nucleotide biosynthesis genes is significantly upregulated when incubated in serum and during ExPEC infection

Supplementation of purines in serum inhibited the upregulation of de novo purine biosynthesis genes in ExPEC

PurR is a transcriptional repressor that regulates the expression of de novo purine biosynthesis genes and plays a role in the pathogenesis of ExPEC

Purines modulate the binding of PurR to its target genes

Discussion

Materials and methods

Ethics statement

Bacterial strains and culture conditions

Transposon-directed screening of genes essential for serum survival

RNA-sequencing and data analysis

Animal experiments

Cell adhesion and intracellular survival assay

Quantitative Real-Time PCR (RT-qPCR) analysis

Protein-ligand docking with Alphafold3

Quantitation of intracellular concentrations of purines

Electrophoretic mobility shift assay

Statistical analysis

Supporting information

S1 Fig. Growth curves of ExPEC and commensal E. coli in serum.

S2 Fig. Growth curves of deletion mutants and their complemented strains of de novo nucleotide biosynthesis genes in serum.

S3 Fig. Western blotting analysis of PurR expression.

S1 Table. Bacterial strains used in this study.

References